PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …

Importance The combination of immune checkpoint inhibitors with antiangiogenic agents
has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC) …

Liver cancer is the fourth most prevalent and the second most lethal cancer in China.
Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma …

Background: Systemic therapy for hepatocellular carcinoma (HCC) consisting of the tyrosine
kinase inhibitor sorafenib has remained unchanged for over a decade, although results from …

Background & Aims Hepatocellular carcinoma (HCC), the most common primary liver
cancer, remains a deadly cancer, with an incidence that has tripled in the United States …

The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with
sorafenib demonstrating survival benefit in the first-line setting and becoming the first …

Background: Patients with advanced hepatocellular carcinoma (HCC) have a poor
prognosis. First-line sorafenib has been the standard of care for a decade, but the treatment …

Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has
increased significantly over the past five years. Sorafenib was the first multikinase inhibitor …

Importance The treatment landscape for advanced hepatocellular carcinoma (HCC) has
recently changed and become relatively confusing. Head-to-head comparisons between …

The treatment landscape for advanced hepatocellular carcinoma has changed dramatically
over the past 4 years. We now have numerous options for patients in frontline, second-line …